Related references
Note: Only part of the references are listed.Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis
R. Park et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events
Linda Chan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
Mari Aso et al.
ONCOLOGIST (2020)
Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Huaxia Yang et al.
CLINICAL IMMUNOLOGY (2020)
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Kazutaka Hosoya et al.
CLINICAL LUNG CANCER (2020)
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy
Satya Das et al.
ONCOLOGIST (2020)
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Xiaoxiang Zhou et al.
BMC MEDICINE (2020)
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Koji Haratani et al.
BMC MEDICINE (2020)
Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis
Doran Ksienski et al.
CLINICAL LUNG CANCER (2019)
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
Beung-Chul Ahn et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab
Hiroki Ishihara et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors
Jun Fukihara et al.
CLINICAL LUNG CANCER (2019)
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Ken Masuda et al.
BMC CANCER (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer
Mathieu Grangeon et al.
CLINICAL LUNG CANCER (2019)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (vol 28, pg 1368, 2017)
N. Chaput et al.
ANNALS OF ONCOLOGY (2019)
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Takeo Fujii et al.
INVESTIGATIONAL NEW DRUGS (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Immune-related adverse events of immune checkpoint inhibitors: a brief review
G. Myers
CURRENT ONCOLOGY (2018)
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Shunsuke Teraoka et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Challenges of Guarantee-Time Bias
Anita Giobbie-Hurder et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Share Paper
